Scientists hunt for clues to catch ALS before symptoms start
NCT ID NCT07213440
First seen Jun 24, 2026 · Last updated Jul 08, 2026 · Updated 4 times
Summary
This study aims to find early markers for ALS by analyzing blood, urine, spinal fluid, tears, and smell tests in 60 people. It includes those with ALS gene mutations but no symptoms, early ALS patients, and healthy controls. The goal is to enable earlier diagnosis and better treatment.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a way to diagnose ALS earlier, which may improve treatment timing and outcomes.
- What could go wrong
- This is an observational study with only 60 participants, so results may not apply to everyone. It focuses on finding markers, not testing a treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Sep 2024
- Expected to finish
-
Apr 2027
An estimate. End dates often move.
- Lead sponsor
-
A government agency
The lead sponsor is a government body.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 90 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: FIRST GROUP: Premotor gene mutation carriers (PGMC): * 18-90 years of age * Provision of a written informed consent * Affiliation with a social security scheme or beneficiary of such a scheme * Diagnosed by a clinically certified laboratory with a disease- causing mutation in a known ALS gene by predictive genetic testing * No symptoms of motor neuron disease explainable otherwise than by mutation in a known ALS gene SECOND GROUP: Control subjects to premotor gene mutation carriers (CTR): * 18-90 years of age * Provision of a written informed consent * Affiliation with a social security scheme or beneficiary of such a scheme * No known genetic mutation and no known ALS disease in close family * No diagnosed motor-neuron disease THIRD GROUP: ALS (EALS) / ALS mimics (MIM) * 18-90 years of age * provision of a written informed consent * affiliation with a social security scheme or beneficiary of such a scheme * Patients with pure motor symptom or early ALS (EALS) or ALS mimics (MIM) EALS are patients with pure motor symptom / early motor symptoms of ALS, including those, where the diagnosis of ALS can already be made. These may be patients who meet the following criteria: According to El Escorial criteria : patients who can be classified as possible ALS or those who show upper motor neuron (UMN) signs only or lower motor neuron (LMN) signs only, so that classification as possible ALS is also not possible. Symptoms should not persist for more than 12 months. According to Gold Coast criteria: Patients who do not fulfill the criterion of temporal progression or patients who only show UMN signs or only LMN signs in one region and thus do not fulfill the diagnostic criteria of ALS. Exclusion Criteria: * Inability to express consent to the study * Persons subject to a judicial safeguard measure, under guardianship or curatorship. * Linguistic incapacity or psychic refusal to read the information. * Pregnant women * Foreseen inability to attend scheduled visits * Persons refusing to take one of the following samples: Acquisition of blood samples, Acquisition of tear fluid samples, Acquisition of urine sample
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Amyotrophic lateral sclerosis (ALS) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
CHU Tours
RECRUITINGTours, France, 37000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gut bacteria may hold clues to dozens of diseases
- Can a magnetic helmet slow ALS? trial tests brain stimulation at home
- Could everyday antioxidants be a weapon against ALS?
- Can a new PET tracer light up the protein behind some dementias and ALS?
- Can a Custom-Made genetic drug slow ALS?
- Can a One-Time gene shot calm inflammation in ALS?